For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.
Welcome to the Weill Cornell Medicine (WCM) Conflict of Interest Office ("COI"). On this page, you will find information to assist you in understanding the meaning of the terms "Conflict of Interest" and "Conflict of Commitment." We also provide information concerning University and federal policies regarding conflicts of interest.
All WCM faculty members and staff are required to complete the Conflicts Survey. The Conflicts Survey is required at a minimum once annually; however, should any financial interests change over the course of the year, an update to the Conflicts Survey is required within 30 days of the change.
For those who have no interests to disclose, the submission of the Conflicts Survey is required as a certification of such. If you have financial interests to disclose you will be required to answer the initial questions plus an additional set of questions for each entity with which you have a financial interest. For example, if you have financial interests in three different entities, you will be required to answer the additional set of questions for each of those entities.
If you are an investigator on research that is overseen by the Food & Drug administration (FDA), you will also need to report financial conflicts to the research sponsor for their reporting, as required, to the FDA. Further information on conflicts reporting in FDA-Sponsored Research.
Please refer to the Policies and Forms section below for specific definitions on what constitutes a financial interest and/or commitment that may be a conflict to the institution.
External Consulting Agreements are considered to be personal arrangements between the WCM faculty member and the Company. Therefore, WCM does not provide legal review or negotiation assistance for such agreements or, otherwise, represent faculty members in this individual capacity. However, for WCM’s protection, University Counsel requires that a non-negotiable Addendum be signed by the Company and incorporated into all employee Consulting Agreements. The faculty member will also need his/her department chairperson’s approval in order to pursue the outside consulting, and must update their Conflicts Survey accordingly.
To download the Model Addendum for Consulting Agreements, click here.
Travel disclosures can be made through your conflicts survey in Weill Research Gateway.
Reimbursed travel expenses and other compensation greater than $5,000 per year in aggregate from a single U.S. non-profit entity need to be reported.
You only must report travel sponsored or reimbursed by a single U.S. non-profit entity if:
You do not have to report travel reimbursed or paid for by Cornell University, nor travel paid by:
There are additional rules for individuals applying for or funded by Public Health Services (PHS), which includes the National Institutes of Health (NIH) and other non-profit agencies that chose to invoke PHS COI policy.
Sponsored travel means (a) travel expenses paid to an investigator or travel paid on an Investigator's behalf, by a single entity in any 12 month period and/or (b) travel reimbursed to or paid on behalf of an Investigator's spouse and dependent children by a single entity in any 12 month period.
All paid or reimbursed travel paid or reimbursed by "for-profit" entities must be disclosed within 30 days of completing travel.
If you need further explanation about the Conflicts Survey, please contact the Conflict of Interest Office at (646) 962-8200 or conflicts@med.cornell.edu.
Research personnel on any grants or contracts funded by an agency or organization that follows the Public Health Service (PHS) FCOI regulations (NIH, AHRQ, ACS, AHA, CDC, etc.) are required to complete conflicts training. This training must be renewed every four years.
Training is available via the Weill Research Gateway (WRG) by using your WCM CWID and password.
Please visit: CITI Training Instructions for instructions, additional information, and FAQs.
All external (non-WCM) investigators and research personnel must complete an External Study Specific Report (SSR) regardless of whether or not they have any relationships to disclose.
To download the WCM External SSR, click here.
WCM is committed to overseeing the conduct of research in a manner that ensures the integrity of the research process and maintains the public trust and that of sponsors in the integrity and credibility of its faculty, its staff, and its research programs. Cornell's policy 1.7, Financial Conflict of Interest describes WCM's commitment and procedures related to the identification and management of real or apparent conflicts of interest that arise from the intersection of personal financial interests and research activities.
To comply with the Public Health Service (PHS) regulations on Responsibility of Applicants for Promoting Objectivity in Research for which PHS Funding is Sought [(42 C.F.R. Part 50, Subpart F) and Responsible Prospective Contractors (45 C.F.R. Part 94)], Weill Cornell Medicine will make available within 5 business days upon receipt of a request as described below, of information concerning Significant Financial Interest (SFI) disclosed to WCM that meets the following criteria:
NIH (National Institutes of Health) Conflicts of Interest (COI) Training Requirements FAQs
The Open Payments Program facilitates greater transparency with regard to financial relationships between manufacturers, physicians and teaching hospitals. This legislation requires that manufacturers of drugs, devices, biologicals and medical supplies report to the Centers for Medicare & Medicaid Services (CMS) any payments or other transfers of value made to physicians and teaching hospitals. "Physicians" include those who are legally authorized to practice medicine, osteopathy, dentistry, dental surgery, podiatry, optometry and chiropractic medicine (note that medical residents are specifically excluded from this definition). Additional information for physicians about the Open Payment Program is available from the Centers for Medicare & Medicaid Services.
WCM-Q is part of Cornell University and functions as an entity of the WCM-NY Conflict of Interest Office.
All research team members, external and internal, who will be conducting human subject research in collaboration with WCM-Q must complete the manual WCM-Q COI Study Specific Form (provided in the link below) regardless of whether or not they have any relationships to disclose.
For Animal Research, all External animal researchers (other than WCM-NY, the Hospital for Special Surgery (HSS), and the Memorial Sloan Kettering Cancer Center (MSK)) who are listed on grants as sub awardees must complete the WCM-Q COI Study Specific Form (provided in the link below) regardless of whether or not they have any relationships to disclose.
To download the WCM-Q COI Study Specific Form, click here.
January 19, 2021: Be advised that the federal government has imposed reporting requirements on all persons travelling to China, Russia, or Venezuela. Under the Export Administration Regulations (EAR), every person that travels to China, Russia, and Venezuela, must report all items carried into the above countries. Click here for full memo.
July 7, 2020: The Centers for Medicare & Medicaid Services’ Open Payments System (Open Payments) published Open Payments Program Year 2019 data, along with newly submitted and updated payment records for previous program years. The data is accessible at https://openpaymentsdata.cms.gov/. Physicians have until the end of the calendar year, in which the data is first published, to log in to review and, if necessary, to dispute the data that have been reported to the government by industry about payments made to them during the 2019 calendar year. Click here for full announcement.
July 1, 2020: Acting Manhattan U.S. Attorney announces $678 million settlement of fraud lawsuit against Novartis Pharmaceuticals Corporation for operating sham speaker programs through which it paid over $100 million to doctors to unlawfully induce them to prescribe Novartis cardiovascular and diabetes drugs reimbursed by federal healthcare programs. Click here for full story.